Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study

Completed · Not applicable

Conditions studied: Cervical Cancer

In brief

Rationale: Diagnostic procedures, such as positron emission tomography (PET) using fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients with cervical cancer The purpose of this study is to evaluate the change in cervical tumor heterogenity as measured by FDG-PET/CT imaging.

Key facts

Study ID: NCT00907140
Run by: Washington University School of Medicine
People needed: 25
Starts: 2008-08-01
Expected to finish: 2016-12-01
Last updated by the study team: 2017-01-20

Who can join

Age: 18 and older, up to 100. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Biopsy-proven cervical cancer. (FIGO stage-Ib2-IVa)
Age ≥ 18
Able to receive chemoradiation therapy with Cisplatin.
Non-pregnant status in women of childbearing potential.
No other active cancer at the time of diagnosis of cervical cancer Patients cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past 5 years.
Patients with distant metastatic disease are eligible provided the estimated survival of the patient is at least 1 year.
Scheduled to undergo or have already undergone FDG-PET/CT imaging for clinical staging of cervical cancer at Barnes-Jewish Hospital Clinical PET Facility on a Biograph 40 PET/CT scanner
Able to give informed consent

You may not qualify if…

Age < 18
Patients with a known active malignancy other than cervical carcinoma.
Pregnant and breastfeeding patients.
Subjects whose tumors are not FDG avid on baseline standard of care FDG-PET/CT imaging

Where it is running

Washington University at St. Louis — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.